AnaptysBio, Inc. ANAB Noncash Advance Future Royalties Interest Expense
Noncash Advance Future Royalties Interest Expense at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by AnaptysBio, Inc. in its filing.
Tagged under the XBRL concept anab:NoncashAdvanceFutureRoyaltiesInterestExpense.
The official record: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about AnaptysBio, Inc.'s noncash advance future royalties interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AnaptysBio, Inc.'s noncash advance future royalties interest expense?
- AnaptysBio, Inc. (ANAB) reported noncash advance future royalties interest expense of $20.86M in Q1 2026.
- How has AnaptysBio, Inc.'s noncash advance future royalties interest expense changed year-over-year?
- AnaptysBio, Inc.'s noncash advance future royalties interest expense increased by 15.5% year-over-year, from $18.06M to $20.86M.
- What is the long-term trend for AnaptysBio, Inc.'s noncash advance future royalties interest expense?
- Over 4 years (2021 to 2025), AnaptysBio, Inc.'s noncash advance future royalties interest expense has grown at a 172.4% compound annual growth rate (CAGR), from $1.45M to $79.89M.
- What does noncash advance future royalties interest expense mean?
- This represents the non-cash interest expense associated with financing arrangements where the company receives upfront capital in exchange for future royalty payments. It reflects the cost of alternative financing structures used to fund operations without immediate equity dilution. Investors should track this to understand the impact of debt-like obligations on long-term profitability and cash flow commitments.